Schear Investment Advisers LLC Acquires 153 Shares of Cencora, Inc. (NYSE:COR)

Schear Investment Advisers LLC increased its holdings in Cencora, Inc. (NYSE:COR) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,241 shares of the company’s stock after buying an additional 153 shares during the quarter. Schear Investment Advisers LLC’s holdings in Cencora were worth $1,402,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in COR. Portfolio Design Labs LLC increased its position in Cencora by 76.9% in the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company’s stock worth $2,479,000 after buying an additional 4,794 shares in the last quarter. Latitude Advisors LLC bought a new position in shares of Cencora during the 4th quarter valued at approximately $559,000. Savant Capital LLC increased its holdings in Cencora by 4.1% in the 4th quarter. Savant Capital LLC now owns 7,312 shares of the company’s stock worth $1,643,000 after acquiring an additional 291 shares in the last quarter. Harbour Trust & Investment Management Co raised its stake in Cencora by 7.7% during the 4th quarter. Harbour Trust & Investment Management Co now owns 10,205 shares of the company’s stock worth $2,293,000 after acquiring an additional 727 shares during the period. Finally, WCM Investment Management LLC lifted its holdings in Cencora by 99.1% during the fourth quarter. WCM Investment Management LLC now owns 2,116 shares of the company’s stock valued at $476,000 after purchasing an additional 1,053 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,187 shares of company stock valued at $17,790,912. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on COR shares. Evercore ISI increased their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Robert W. Baird raised their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Up 0.2 %

Shares of NYSE:COR opened at $246.86 on Wednesday. The company has a 50-day moving average price of $238.86 and a 200 day moving average price of $237.03. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a market cap of $47.71 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.